199 related articles for article (PubMed ID: 22426127)
21. Multifaceted counter-APOBEC3G mechanisms employed by HIV-1 Vif.
Britan-Rosich E; Nowarski R; Kotler M
J Mol Biol; 2011 Jul; 410(5):1065-76. PubMed ID: 21763507
[TBL] [Abstract][Full Text] [Related]
22. Estimating the fraction of progeny virions that must incorporate APOBEC3G for suppression of productive HIV-1 infection.
Thangavelu PU; Gupta V; Dixit NM
Virology; 2014 Jan; 449():224-8. PubMed ID: 24418556
[TBL] [Abstract][Full Text] [Related]
23. APOBEC3G is degraded by the proteasomal pathway in a Vif-dependent manner without being polyubiquitylated.
Dang Y; Siew LM; Zheng YH
J Biol Chem; 2008 May; 283(19):13124-31. PubMed ID: 18326044
[TBL] [Abstract][Full Text] [Related]
24. DNA mutagenic activity and capacity for HIV-1 restriction of the cytidine deaminase APOBEC3G depend on whether DNA or RNA binds to tyrosine 315.
Polevoda B; Joseph R; Friedman AE; Bennett RP; Greiner R; De Zoysa T; Stewart RA; Smith HC
J Biol Chem; 2017 May; 292(21):8642-8656. PubMed ID: 28381554
[TBL] [Abstract][Full Text] [Related]
25. Distinct domains within APOBEC3G and APOBEC3F interact with separate regions of human immunodeficiency virus type 1 Vif.
Russell RA; Smith J; Barr R; Bhattacharyya D; Pathak VK
J Virol; 2009 Feb; 83(4):1992-2003. PubMed ID: 19036809
[TBL] [Abstract][Full Text] [Related]
26. Identification of amino acid residues in HIV-1 Vif critical for binding and exclusion of APOBEC3G/F.
Yamashita T; Kamada K; Hatcho K; Adachi A; Nomaguchi M
Microbes Infect; 2008; 10(10-11):1142-9. PubMed ID: 18603011
[TBL] [Abstract][Full Text] [Related]
27. Status of APOBEC3G/F in cells and progeny virions modulated by Vif determines HIV-1 infectivity.
Yamashita T; Nomaguchi M; Miyake A; Uchiyama T; Adachi A
Microbes Infect; 2010 Feb; 12(2):166-71. PubMed ID: 19944180
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of HIV-1 infection and replication by enhancing viral incorporation of innate anti-HIV-1 protein A3G: a non-pathogenic Nef mutant-based anti-HIV strategy.
Green LA; Liu Y; He JJ
J Biol Chem; 2009 May; 284(20):13363-13372. PubMed ID: 19324886
[TBL] [Abstract][Full Text] [Related]
29. HIV-1 viral infectivity factor (Vif) alters processive single-stranded DNA scanning of the retroviral restriction factor APOBEC3G.
Feng Y; Love RP; Chelico L
J Biol Chem; 2013 Mar; 288(9):6083-94. PubMed ID: 23316055
[TBL] [Abstract][Full Text] [Related]
30. Multi-scale modeling of HIV infection in vitro and APOBEC3G-based anti-retroviral therapy.
Hosseini I; Mac Gabhann F
PLoS Comput Biol; 2012 Feb; 8(2):e1002371. PubMed ID: 22346743
[TBL] [Abstract][Full Text] [Related]
31. Simian Immunodeficiency Virus Vif and Human APOBEC3B Interactions Resemble Those between HIV-1 Vif and Human APOBEC3G.
Wang J; Shaban NM; Land AM; Brown WL; Harris RS
J Virol; 2018 Jun; 92(12):. PubMed ID: 29618650
[TBL] [Abstract][Full Text] [Related]
32. The HDAC6/APOBEC3G complex regulates HIV-1 infectiveness by inducing Vif autophagic degradation.
Valera MS; de Armas-Rillo L; Barroso-González J; Ziglio S; Batisse J; Dubois N; Marrero-Hernández S; Borel S; García-Expósito L; Biard-Piechaczyk M; Paillart JC; Valenzuela-Fernández A
Retrovirology; 2015 Jun; 12():53. PubMed ID: 26105074
[TBL] [Abstract][Full Text] [Related]
33. APOBEC3G inhibits elongation of HIV-1 reverse transcripts.
Bishop KN; Verma M; Kim EY; Wolinsky SM; Malim MH
PLoS Pathog; 2008 Dec; 4(12):e1000231. PubMed ID: 19057663
[TBL] [Abstract][Full Text] [Related]
34. Characterization of conserved motifs in HIV-1 Vif required for APOBEC3G and APOBEC3F interaction.
He Z; Zhang W; Chen G; Xu R; Yu XF
J Mol Biol; 2008 Sep; 381(4):1000-11. PubMed ID: 18619467
[TBL] [Abstract][Full Text] [Related]
35. Regulation of APOBEC3 proteins by a novel YXXL motif in human immunodeficiency virus type 1 Vif and simian immunodeficiency virus SIVagm Vif.
Pery E; Rajendran KS; Brazier AJ; Gabuzda D
J Virol; 2009 Mar; 83(5):2374-81. PubMed ID: 19109396
[TBL] [Abstract][Full Text] [Related]
36. An anti-HIV-1 compound that increases steady-state expression of apoplipoprotein B mRNA-editing enzyme-catalytic polypeptide-like 3G.
Ejima T; Hirota M; Mizukami T; Otsuka M; Fujita M
Int J Mol Med; 2011 Oct; 28(4):613-6. PubMed ID: 21725586
[TBL] [Abstract][Full Text] [Related]
37. Phosphorylation of APOBEC3G by protein kinase A regulates its interaction with HIV-1 Vif.
Shirakawa K; Takaori-Kondo A; Yokoyama M; Izumi T; Matsui M; Io K; Sato T; Sato H; Uchiyama T
Nat Struct Mol Biol; 2008 Nov; 15(11):1184-91. PubMed ID: 18836454
[TBL] [Abstract][Full Text] [Related]
38. APOBEC3G and APOBEC3F require an endogenous cofactor to block HIV-1 replication.
Han Y; Wang X; Dang Y; Zheng YH
PLoS Pathog; 2008 Jul; 4(7):e1000095. PubMed ID: 18604271
[TBL] [Abstract][Full Text] [Related]
39. The HIV-1 central polypurine tract functions as a second line of defense against APOBEC3G/F.
Hu C; Saenz DT; Fadel HJ; Walker W; Peretz M; Poeschla EM
J Virol; 2010 Nov; 84(22):11981-93. PubMed ID: 20844042
[TBL] [Abstract][Full Text] [Related]
40. HIV-1 Vif-mediated ubiquitination/degradation of APOBEC3G involves four critical lysine residues in its C-terminal domain.
Iwatani Y; Chan DS; Liu L; Yoshii H; Shibata J; Yamamoto N; Levin JG; Gronenborn AM; Sugiura W
Proc Natl Acad Sci U S A; 2009 Nov; 106(46):19539-44. PubMed ID: 19887642
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]